Elaine Maria Pereira

Elaine Maria Pereira

Auto-generated profile, based on publicly available information

Elaine Maria Pereira

Department of Pediatrics Columbia University Irving Medical Center New York New York USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2022 in Annals of Neurology
Verified
Journal Article
Open access
KPKonrad Platzer
Konrad Platzer
HSHeinrich Sticht
Heinrich Sticht
Caleb BuppCaleb Bupp
Caleb Bupp
MGMythily Ganapathi
Mythily Ganapathi
EPElaine M. Pereira
Elaine M. Pereira
SWSonja M. Wojcik
Sonja M. Wojcik
Objective: Rare inherited missense variants in SLC32A1, the gene that encodes the vesicular gamma‐aminobutyric acid (GABA) transporter, have recently been shown to cause genetic epilepsy with febrile seizures plus. We aimed to clarify if de novo missense variants in SLC32A1 can also cause epilepsy with impaired neurodevelopment.Methods: Using exome sequencing, we identified four individuals with a developmental and epileptic encephalopathy and de novo missense variants in SLC32A1. To assess causality, we performed functional evaluation of the identified variants in a murine neuronal cell culture model.Results: The main phenotype comprises moderate‐to‐severe intellectual disability, infantile‐onset epilepsy within the first 18 months of life, and a choreiform, dystonic, or dyskinetic movement disorder. In silico modeling and functional analyses reveal that three of these variants, which are located in helices that line the putative GABA transport pathway, result in reduced quantal size, consistent with impaired filling of synaptic vesicles with GABA. The fourth variant, located in the vesicular gamma‐aminobutyric acid N‐terminus, does not affect quantal size, but increases presynaptic release probability, leading to more severe synaptic depression during high‐frequency stimulation. Thus, variants in vesicular gamma‐aminobutyric acid can impair GABAergic neurotransmission through at least two mechanisms, by affecting synaptic vesicle filling and by altering synaptic short‐term plasticity.Interpretation: This work establishes de novo missense variants in SLC32A1 as a novel cause of a developmental and epileptic encephalopathy.Summary for Social Media If Published: @platzer_k @lemke_johannes @RamiJamra @Nirgalito @GeneDx The SLC family 32 Member 1 (SLC32A1) is the only protein identified to date, that loads gamma‐aminobutyric acid (GABA) and glycine into synaptic vesicles, and is therefore also known as the vesicular GABA transporter (VGAT) or vesicular inhibitory amino acid transporter (VIAAT). Rare inherited missense variants in SLC32A1, the gene that encodes VGAT/vesicular inhibitory amino acid transporter, have recently been shown to cause genetic epilepsy with febrile seizures plus. We aimed to clarify if de novo missense variants in SLC32A1 can also cause epilepsy with impaired neurodevelopment. We report on four individuals with de novo missense variants in SLC32A1 and a developmental and epileptic encephalopathy with infantile onset epilepsy. We establish causality of the variants via in silico modeling and their functional evaluation in a murine neuronal cell culture model. SLC32A1 variants represent a novel genetic etiology in neurodevelopmental disorders with epilepsy and a new GABA‐related disease mechanism. ANN NEUROL 2022;92:958–973

6 September 2021 in Genetics in Medicine
Verified
Journal Article
Closed access
EPElaine M. Pereira
Elaine M. Pereira
PAPriyanka Ahimaz
Priyanka Ahimaz
CACarli Andrews
Carli Andrews
KAKwame Anyane-Yeboa
Kwame Anyane-Yeboa
TATodor Arsov
Todor Arsov
RWRonald J. Wapner
Ronald J. Wapner

5 August 2023 in Genetics in Medicine
Verified
Journal Article
Open access
EBElisabeth Bosch
Elisabeth Bosch
BPBernt Popp
Bernt Popp
EGEsther Güse
Esther Güse
CSCindy D. Skinner
Cindy D. Skinner
ESEline van der Sluijs
Eline van der Sluijs
GVGeorgia Vasileiou
Georgia Vasileiou
Coffin-Siris and Nicolaides-Baraitser syndromes, are recognisable neurodevelopmental disorders caused by germline variants in BAF complex subunits. The SMARCC2 BAFopathy was recently reported. Herein, we present clinical and molecular data on a large cohort. Clinical symptoms for 41 novel and 24 previously published affected individuals were analyzed using the Human Phenotype Ontology. For genotype-phenotype correlation, molecular data were standardized and grouped into non-truncating and likely gene-disrupting (LGD) variants. Missense variant protein expression and BAF subunit interactions were examined using 3D protein modeling, co-immunoprecipitation, and proximity-ligation assays. Neurodevelopmental delay with intellectual disability, muscular hypotonia and behavioral disorders were the major manifestations. Clinical hallmarks of BAFopathies were rare. Clinical presentation differed significantly, with LGD variants being predominantly inherited and associated with mildly reduced or normal cognitive development, while non-truncating variants were mostly de novo and presented with severe developmental delay. These distinct manifestations and non-truncating variant clustering in functional domains suggest different pathomechanisms. In vitro testing showed decreased protein expression for N-terminal missense variants similar to LGD. This study improved SMARCC2 variant classification and identified discernible SMARCC2-associated phenotypes for LGD and non-truncating variants, which were distinct from other BAFopathies. The pathomechanism of most non-truncating variants has yet to be investigated.

18 March 2019 in BMC Medical Genomics
Verified
Journal Article
Open access
PDF file
WKWahab A. Khan
Wahab A. Khan
NCNinette Cohen
Ninette Cohen
Stuart ScottStuart Scott
Stuart Scott
EPElaine M. Pereira
Elaine M. Pereira
The chromosome 3q29 microdeletion syndrome is characterized by a clinical phenotype that includes behavioral features consistent with autism and attention deficit hyperactivity disorder, mild to moderate developmental delay, language-based learning disabilities, and/or dysmorphic features. In addition, recent data suggest that adults with chromosome 3q29 microdeletions have a significantly increased risk for psychosis and neuropsychiatric phenotypes. We report a 3-year-old male with global developmental delay, anemia, and mild dysmorphic facial features. Clinical chromosomal microarray (CMA) testing of the proband detected a heterozygous 1.21 Mb deletion at chromosome 3q29, consistent with a diagnosis of the 3q29 microdeletion syndrome. Interestingly, subsequent parental testing determined that the pathogenic deletion was inherited from his otherwise healthy mother who had a history of learning disabilities. The chromosome 3q29 microdeletion was not detected in the healthy older sibling of the proband by CMA testing, nor was it prenatally detected in a subsequent maternal pregnancy. Our report highlights the 3q29 microdeletion syndrome as an illustrative example of the importance of a molecular diagnosis for families that harbor pathogenic copy number aberrations with variable expressivity, in particular those that also impart an increased risk for adult onset neuropsychiatric phenotypes.

9 April 2023 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
ATAmanda Thomas‐Wilson
Amanda Thomas‐Wilson
JSJohn P. Schacht
John P. Schacht
DCDavid Chitayat
David Chitayat
SBSusan Blaser
Susan Blaser
FSFrancis Jeshira Reynoso Santos
Francis Jeshira Reynoso Santos
MGMythily Ganapathi
Mythily Ganapathi

15 December 2023 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
AFAndrew Freiman
Andrew Freiman
ARAisha Rekab
Aisha Rekab
ABAmanda L. Bergner
Amanda L. Bergner
EPElaine M. Pereira
Elaine M. Pereira
YLYuhuan Lin
Yuhuan Lin
PAPriyanka Ahimaz
Priyanka Ahimaz